Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for Amylyx Pharmaceuticals in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.52) per share for the quarter. The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($2.20) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals' Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.49) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at ($1.70) EPS and FY2028 earnings at ($1.40) EPS.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million during the quarter.
Other research analysts have also recently issued research reports about the stock. Mizuho raised shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $3.00 to $7.00 in a report on Monday, April 7th. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $8.00.
Check Out Our Latest Stock Report on AMLX
Amylyx Pharmaceuticals Stock Performance
Amylyx Pharmaceuticals stock traded up $0.22 during midday trading on Wednesday, reaching $4.20. 284,818 shares of the stock were exchanged, compared to its average volume of 1,277,517. Amylyx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $7.27. The firm has a market cap of $372.13 million, a PE ratio of -1.10 and a beta of -0.53. The company's fifty day moving average is $3.56 and its 200-day moving average is $4.11.
Institutional Investors Weigh In On Amylyx Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. increased its stake in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after buying an additional 4,883 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $45,000. Alpine Global Management LLC purchased a new position in shares of Amylyx Pharmaceuticals in the 4th quarter valued at approximately $45,000. RPO LLC bought a new position in Amylyx Pharmaceuticals in the fourth quarter worth $46,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth about $53,000. Hedge funds and other institutional investors own 95.84% of the company's stock.
Insider Activity at Amylyx Pharmaceuticals
In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 11,851 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $3.47, for a total transaction of $41,122.97. Following the completion of the sale, the chief executive officer now directly owns 3,201,247 shares in the company, valued at $11,108,327.09. This represents a 0.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Camille L. Bedrosian sold 12,425 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $43,114.75. Following the completion of the transaction, the insider now owns 194,375 shares in the company, valued at approximately $674,481.25. This represents a 6.01 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 64,509 shares of company stock valued at $222,586. Corporate insiders own 11.70% of the company's stock.
About Amylyx Pharmaceuticals
(
Get Free Report)
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
See Also
Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
